An orally bioavailabe tyrosine kinase inhibitor, targeting MET (or c-MET); it selectively binds to and inhibits mesenchymal epithelial transition (low nM Ki values and >1000 fold selective relative to 208 kinases) with potential antineoplastic activity.

SL Timofeevski et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry. 2009, 48(23), 5339-49.